Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients.

We report high SVR rates in a real-world diverse cohort of HCV-infected patients treated with second-generation direct-acting antivirals. The results highlight the importance of conducting real-world analyses to elucidate clinical factors associated with poorer outcomes that may not be identified in registration trials. PMID: 29305405 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/29305405?dopt=Abstract

Source: cmaj - January 5, 2018 Category: General Medicine Authors: Aspinall AI, Shaheen AA, Kochaksaraei GS, Haslam B, Lee SS, Macphail G, Kapler J, Larios OE, Burak KW, Swain MG, Borman MA, Coffin CS Tags: CMAJ Open Source Type: research